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Abstract
Motivation: Modelling methods that find structure in data are neces-
sary with the current large volumes of genomic data, and there have
been various efforts to find subsets of genes exhibiting consistent
patterns over subsets of treatments. These biclustering techniques
have focused on one data source, often gene expression data. We
present a Bayesian approach for joint biclustering of multiple data
sources, extending a recent method Group Factor Analysis (GFA) to
have a biclustering interpretation with additional sparsity assump-
tions. The resulting method enables data-driven detection of linear
structure present in parts of the data sources. Results: Our sim-
ulation studies show that the proposed method reliably infers bi-
clusters from heterogeneous data sources. We tested the method on
data from the NCI-DREAM drug sensitivity prediction challenge,
resulting in an excellent prediction accuracy. Moreover, the pre-
dictions are based on several biclusters which provide insight into
the data sources, in this case on gene expression, DNA methylation,
protein abundance, exome sequence, functional connectivity finger-
prints and drug sensitivity. Availability: http://research.
cs.aalto.fi/pml/software/GFAsparse/
1 Introduction
Numerous clustering approaches have advanced to extract knowl-
edge from sets of e.g. gene expression experiments, when condi-
tions of the samples are either not known or researchers are inter-
ested in dependencies within or across experiments. Conditions or
treatments can affect the expression levels of certain genes only,
and similarly, many genes are likely to be co-regulated under certain
conditions only. For this purpose, biclustering techniques have been
developed (Cheng and Church, 2000; Hartigan, 1972; Lazzeroni
et al., 2002; Morgan and Sonquist, 1963). Biclustering is tradition-
ally defined as simultaneously clustering both rows and columns in
a data matrix. Depending on the metric and the data, different ap-
proaches have emerged, aiming to cluster genes based on their ex-
pression levels being the same, differing by a constant, or being lin-
early dependent, with respect to different conditions (Madeira and
Oliveira, 2004). Hochreiter et al. (2010) introduced a generative ap-
proach called Factor Analysis for Bicluster Acquisition (FABIA),
accounting for linear dependencies between gene expression and
conditions. The biclusters are factors of the measurement matrix,
and hence can be overlapping in both genes and conditions, whereas
many approaches are limited to distinct clusters. Each bicluster can
also include oppositely regulated genes (up- and down-regulated)
across conditions. Similar approaches have been proposed by Car-
valho et al. (2008) and Gao et al. (2014), with the latter one addi-
tionally focusing on the inference of gene co-expression networks.
FABIA has also been extended to better suit genotype data (Hochre-
iter, 2013).
Waltman et al. (2010) proposed an algorithm for simultaneous bi-
clustering of heterogeneous multiple species data collections. They
investigate the identification of conserved co-regulated gene groups
(modules) by comparing genome-wide datasets for closely related
organisms and the evolution of gene regulatory networks. Most
genes are unlikely to be co-regulated under every possible condi-
tion, and exclusive gene clusters cannot capture the complexity of
transcriptional regulatory networks. Their proposed approach aims
to identify meaningful condition-dependent conserved modules, in-
tegrating data across the same genes present in multiple species.
Inferring bicluster structure jointly from multiple data sources is
potentially more accurate than analysis of a single set, and the dis-
covered relationships between the sources may offer new insights.
In this paper, we extend a recent generative Bayesian modelling
approach, group factor analysis (GFA) (Virtanen et al., 2012; Su-
vitaival et al., 2014; Klami et al., 2015). GFA was developed for
exploratory analysis of multiple data sources (views), resulting in
an interpretable group-sparse factorization of the data collection.
When the factors are additionally variable-wise sparse, as a result
of introducing suitable priors, they are interpretable as biclusters
of multiple co-occurring data sources that need not share the same
features (genes; as opposed to Waltman et al. (2010)). As a fac-
tor model GFA further shares the favourable properties of FABIA.
We demonstrate its use in a multi-view drug sensitivity prediction
task that the previous bicluster methods could not handle naturally:
the approach shows superior prediction performance, and is able to
infer meaningful structure present in subsets of the data.
2 Methods
2.1 Factor analysis
Factor Analysis for Bicluster Acquisition (Hochreiter et al., 2010)
assumes preprocessed and filtered gene expression data Y ∈
IRN×D. Every row represents a sample and every column a gene.
Therefore the value yi,j corresponds to the expression level of the
jth gene in the ith sample. A bicluster is defined as a set of rows
that are similar for a set of columns, and vice versa. The model for
K biclusters is
Y =
K∑
k=1
x:,kw
>
:,k +  , (1)
where each factor k is defined by an outer product of the kth
columns of the factor matrix X ∈ IRN×K and the loading ma-
trix W ∈ IRD×K , and  ∈ IRN×D is normally distributed noise:
n,d ∼ N¸(0, σ2d). The factors are the biclusters, with |wd,k| indicat-
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ing the (soft) membership of gene d in bicluster k, and |xn,k| like-
wise for sample n. Both theW andX are given sparse priors, more
specifically component-wise independent Laplace distributions:
p(W) =
(
1√
2
)DK K∏
k=1
D∏
d=1
e−
√
2|wd,k| (2)
p(X) =
(
1√
2
)NK K∏
k=1
N∏
n=1
e−
√
2|xn,k| . (3)
The parameters are inferred with variational expectation maximiza-
tion, see (Hochreiter et al., 2010) for details.
2.2 Sparse group factor analysis for biclustering
Group factor analysis has been proposed as an extension to factor
analysis for finding factors capturing joint variability between data
sets instead of individual variables (Virtanen et al., 2012; Suvitaival
et al., 2014; Klami et al., 2015). It is designed to deal with sev-
eral data sources Y(1) ∈ IRN×D1 , . . . ,Y(M) ∈ IRN×DM (called
views) of dimensionality Dm with N co-occurring observations.
GFA models the nth sample of the mth data view as
y(m)n ∼ N
(
W(m)xn, τ
−1
m IDm
)
, (4)
where τm is the noise precision of view m. The loading matrix
W(m) is given a sparse prior that allows omitting any component k
from affecting drug data view Y(m). This enables a group-sparse
factorization, where components may be (i) specific to a single data
view, (ii) shared between all the data views or (iii) shared between
any subset of the data views. As we are interested in finding biclus-
ters, we introduce a prior that is additionally variable-wise sparse,
that is, across the elements of the matrices W(m) and X. This is
done similarly to how Khan et al. (2014) produced variable-wise
sparsity, but now for both variables and samples to produce biclus-
ters. Namely we use the following spike and slab priors 1:
xn,k ∼ h(x)n,kN
(
0,
(
α
(x)
k
)−1)
+
(
1− h(x)n,k
)
δ0 (5)
w
(m)
d,k ∼ h(m)d,k N
(
0,
(
α
(m)
k
)−1)
+
(
1− h(m)d,k
)
δ0 (6)
h
(:)
n,k∼Bernoulli(pi
(:)
k ) pi
(:)
k ∼Beta(api,bpi) α
(:)
k ∼Gamma(aα,bα) (7)
where the binary h(m)d,k determines whether the component (biclus-
ter) k is active in the dth feature ofY(m) (for all non-zero n in h(x)n,k),
α
(m)
k determines the scale of the component k in view m and pi
(m)
k
the probability of h(m)d,k = 1. The prior is analogous for samples (i.e.
the rows of the data matrices) through h(x)n,k.Effectively, the spike
and slab prior will set weights that affect the data (likelihood) only
little to 0, which allows direct biclustering interpretations without a
need for arbitrary thresholding afterwards. The model is completed
with a gamma prior for the noise precision parameters τm and un-
informative hyperpriors ([api, bpi, aα, bα, aτ , bτ ] = 1).
In this formulation, the data source information (feature group-
ing) is used in three ways: (i) the noise precision (τm) is the same
for all the features in a view, (ii) the binary vector h(m):,k has a
1Suvitaival et al. (2014) included sparsity for samples and mentioned the con-
nection to biclustering, but the interpretation was not explored further
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Fig. 1: Left: 4 non-overlapping biclusters (coloured blocks) used in the
multi-view data (gray area). Right: The biclusters inferred by GFA.
common probability (pi(m)k ) of being active and (iii) the scale of
a component (α(m)k ) is shared within a view. With an uninforma-
tive Gamma prior, often called Automatic Relevance Determination
prior, this third property implements the group sparsity. The second
property implies that a specific feature d (in view m) is more likely
to be active in a bicluster, if many of the features in view m belong
to the said bicluster, and vice versa. This allows explaining variance
that is not present in all the data sources, but dense in some of them,
more robustly. Given data with significant (source specific) struc-
tured variation respective components can help to detect biclusters
more accurately.
The formulation above assumes that all the data views have
co-occurring samples. We also extend GFA for joint mod-
elling of data sets that are paired in two modes (see Fig. 1),
i.e. {Y(1,1), . . . ,Y(M1,1), Y(1,2), . . .Y(M2,2)}, where Y(m,2) ∈
IRD1,N2 is paired with the features of Y(1,1). Both the modes will
have a set of components identical to the ones presented above with
one exception, and hence we will not repeat the details of the priors
here. The exception is that the view paired in both the modes is
generated from the components of both the modes, as
y
(1,1)
i,j ∼ N
(
w
(1,1)
j x
(1)
i +w
(1,2)
i x
(2)
j , τ
−1
1,1
)
. (8)
As the priors remain conjugate, the model can be inferred using
Gibbs sampling, resulting in linear complexity in bothN andD, but
cubic w.r.t. the number of componentsK. The parameters shown in
this paper, and used in predictive tasks, will be the posterior means.
In the following sections we will test FABIA and GFA in several
simulation studies and a drug sensitivity analysis, incorporating ge-
netic data available from the DREAM project.
3 Simulation study
We show an illustrative example of bicluster inference, generating
a collection of data sets, {Y(1,1),Y(2,1),Y(3,1),Y(1,2)}, with 200
samples and dimensions (100, 50, 60) for Y(:,1), and 100 samples
and dimension (70) for Y(1,2). The data collection was generated
with four biclusters and additional noise with variance 1. The non-
zero parts of x and w for the biclusters were drawn from N (0, 1),
but truncated between absolute values 1 and 2 for illustrative pur-
poses. The data structure is shown in Fig. 1 (left); for clarity the
biclusters are non-overlapping blocks. We inferred the component
structure of these data using GFA; the posterior mean of the biclus-
ters is visualized in Fig. 1 (right). GFA can clearly infer this kind
of component structure very accurately.
GFA has been designed for joint modelling of multiple data sets.
However, when the data consist of one set only, FABIA and GFA
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are essentially the same model; in the current implementations there
is the technical difference that FABIA has a continuous valued spar-
sity prior forX andW, whereas GFA implements a discrete choice
with the spike-and-slap. We first investigate the effect of this techni-
cal difference by comparing GFA with FABIA on single-view data
(FABIA1), and then investigate how much multi-view data helps,
by comparing GFA against FABIA for which data are concatenated
into a single matrix (FABIA2).
For the simulation studies, we construct data from the generative
model Eq. (4), with matrices X and W generated such that each
element is either zero or sampled randomly from the normal distri-
butionN (0, 1) to build the bicluster(s). The resulting data matrices
Y are given to the methods, which then return the bicluster esti-
mates x′:,kw
′>
:,k. They are compared to the true biclusters to analyse
the models’ performance. FABIA is run with the correct number of
biclusters K, and the results are reported for a range of thresholds.
GFA learns the cluster number by driving unnecessary ones to zero,
and we used a component number 5 above the correct K. The final
biclustering is based on 101 posterior samples (2000 burn-in sam-
ples, 20 thinning): if the majority of (x:,kw
(m)>
:,k )ij are non-zero
in the posterior samples, then Y(m)ij is assigned to the kth biclus-
ter, otherwise not. All the simulation studies are repeated 10 times
and we report the average F1 score for detecting the true bicluster
structure:
F1 =
2TP
2TP + FN + FP
(9)
where TP , FN and FP denote the number true positives, false
negatives and false positives, respectively, summed over all the el-
ements of the data matrix. To be able to evaluate the effects of
different sparsity priors and inference techniques, we also compare
to FA with similar priors as GFA, using the full concatenated data,
and inferred with Gibbs sampling. This is done be changing Eq. (5)
to Eq. (7) to allow only single α(1)k and pi
(1)
k across the data features,
and by giving each feature independent noise precision τd.
By default we use M = 5 data views, N = 50 samples,
Dm = 100 features per data view and one bicluster active in 70%
of the samples and the features. Bicluster and noise variance in
the view of interest are set to 1. To make the data views hetero-
geneous, the other 4 data views are given bicluster and noise vari-
ances of ((0.2, 0.2), (5, 5), (0.2, 5), (5, 0.2)). We report the mean
performance of the methods in Fig. 2, in six different experimental
settings:
(a) All data views are set to be homogeneous having variance of 1 in
the bicluster and the noise residual, and the number of data views
is varied. Due to the homogeneity of the data views, GFA has no
advantage over FA. FA outperforms FABIA on high-dimensional
large number of views.
(b) Similar to (a), but with heterogeneous data with respect to the
bicluster and noise residual strength. The multi-view approach of
GFA is superior, while FA and FABIA have similar performance.
(c) Similar to (b), but with sparse biclusters w.r.t. the samples and
group sparse w.r.t. the features (present in all but every 3rd view).
This matches GFA’s assumptions leading to superior results.
(d) Additional view-specific noise components (0 to 6) were added
on top of the bicluster signal (as xnoisew>noise, each vector element
sampled from N (0, 1)). The GFA-type of priors and inference
are clearly more robust against the structured noise.
(e) We evaluated the accuracy of detecting 1 to 7 partly overlapping
biclusters. GFA outperforms FA, whereas FABIA does not seem
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Fig. 2: Simulated experiments comparing the abilities of GFA, FA and
FABIA to detect data-generating biclustering. (a) and (b) report the F1
scores over a varying number of data views (M ) present, for homogeneous
and heterogeneous data collections, respectively. The biclusters are further
assumed group-sparse in (c). In (d) the problem is made more challenging
by adding structured noise on top of the signal, whereas the number of
biclusters is varied in (e). In (f), the strength of the bicluster is varied in the
supporting views. FABIA1 uses only the data matrix of interest, whereas
FABIA2 and FA have side information concatenated with it; both FABIAs
are reported for thresholds (0.01, 0.05, 0.10) determining the biclusters.
very robust when the number of biclusters increases; using the
additional data can even decrease its performance.
(f) The strength of the biclusters is varied for the additional views
(precision α ranging from 10−2 to 102). GFA is more accurate
when the additional views have strong biclusters, and has a simi-
lar performance with FABIA when weaker. FA suffers compared
to FABIA when the additional views get less relevant.
Across all the studies discussed above, GFA was able to detect
the correct number of biclusters (and additional noise components)
exactly in 90.4% of the runs, and overestimated it by 1, 2 or 3 in
9%, 0.4% and 0.1% of the runs, respectively. The extra components
were modelling artificial structure detected in the residual noise and
did not resemble the bicluster structure. To confirm that they did not
give an advantage in the comparison, we also ran FABIA with 5 ex-
tra components, resulting in consistently worse performance com-
pared to the reported runs, where FABIA was given the true com-
ponent amount. The standard deviations of the mean F1 scores,
averaged over the 10 independent repetitions, ranged from 0.003 to
0.01. Inferring a single model took on average 22s, 45s, 0.04s, and
0.5s for GFA, FA, FABIA1 and FABIA2, respectively, demonstrat-
ing the efficiency of the EM-algorithm in FABIA.
Our FA implementation is generally, but not consistently, more
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robust than FABIA in bicluster detection with additional data
sources. The advantages of the multi-view setup of GFA (vs con-
catenation in FA and FABIA2) are most significant when (i) there
are plenty of heterogeneous data views, (ii) the biclusters are group-
sparse, or (iii) the data views are highly heterogeneous. These con-
ditions are realistic in real-life applications.
4 Drug response study
The NCI-DREAM drug sensitivity prediction challenge (Costello
et al., 2014) provided publicly available data consisting of gene ex-
pression (GE), RNA, DNA methylation (MET), copy number vari-
ation (CNV), protein abundance (RPPA) and exome sequence (EX)
measurements for 53 human breast cancer cell lines. In the chal-
lenge, expression data were based on Affymetrix Genome-Wide
Human SNP6.0 Array and Affymetrix GeneChip Human Gene 1.0
ST microarrays. RNA sequencing libraries were prepared using the
TruSeq RNA Sample Preparation Kit and whole transcriptome shot-
gun sequencing was performed. The Mutation status was obtained
from exome-capture sequencing and GenomeStudio Methylation
Module v1.0 was used to express the methylation for each genome-
wide detected CpG locus resulting in values between 0 (completely
unmethylated) to 1 (completely methylated) proportional to the de-
gree of methylation at any particular locus. More details on the
preparation of the genomic data for the challenge are provided by
Costello et al. (2014). Each cell line was exposed to 31 therapeutic
compounds and the dose-response values of growth inhibition were
collected. The drug response data was revealed only for 35 of the
cell lines, and the challenge was to predict the response of the re-
maining 18 cell lines, ranking them from the most sensitive to the
most resistant.
As the drug response prediction problem is extremely challeng-
ing, we performed the following steps, learning from Costello et al.
(2014), to increase the signal-to-noise ratio: We reduced the dimen-
sionality to the 500 genes with the highest average variance over the
data views, including the overlapping set of 14 genes appearing in
the RPPA data set. Furthermore, the most predictive data sources
for further analysis were chosen by 7-fold cross validation on the 35
training samples with known drug response values. To compare the
sources the root mean squared error (RMSE), as well as Pearson
and Spearman correlations of the predicted drug responses, were
computed averaged over 10 repetitions of the experiments, each
with different random splits. We inferred the GFA model for this
multi-view data by ignoring the missing drug response data in the
likelihood, after which the missing values can be predicted from
XW(m), where X for the missing cell lines is inferred based on
the other data sources only. The performance of GFA trained with
different combinations of data views is shown in Table 1.
The most promising views finally chosen for the bicluster analy-
sis were gene expression, methylation, exome sequence and RPPA
measurements, leaving out the copy number variation and RNA.
Finally, we ran GFA for the full data (handling the test drug re-
sponses as missing values) and reconstructed the missing data av-
eraged over the posterior samples of 50 sampling chains. We gave
the model a mildly informative prior assuming signal-to-noise ratio
of 0.5. All the sampler chains were initialized with K = 60, al-
lowing data-driven inference of model complexity (resulting in 48
to 56 components). A total of 100 sampled parameters were stored
for each chain (every 20th sample stored after 10000 burn-in itera-
tions), resulting in an average runtime of 84 minutes per chain. The
performance was quantified using the same score as in the chal-
Table 1: Averaged 7-fold cross validation results for GFA on the training
set of the DREAM7 drug sensitivity prediction challenge to identify the
views showing best prediction performance for further analysis.
Views used RMSE Pearson Spearman
All 1.9 0.031 0.079
GE, MET, CNV, RNA, RPPA 2.3 0.016 0.088
GE, CNV, RNA, RPPA, EX 2.0 0.031 0.078
GE, MET, CNV, RPPA, EX 1.5 0.040 0.085
GE, MET, CNV, RNA, EX 1.8 0.012 0.078
MET, CNV, RNA, RPPA, EX 1.6 0.018 0.058
GE, MET, RNA, RPPA, EX 1.9 0.040 0.089
GE, MET, CNV, RPPA 1.8 0.028 0.071
GE, CNV, RPPA, EX 1.8 0.018 0.074
GE, MET, CNV, EX 1.5 0.024 0.090
MET, CNV, RPPA, EX 2.1 0.020 0.061
GE, MET, RPPA, EX 1.4 0.046 0.087
GE, MET, RPPA 1.9 0.024 0.072
GE, RPPA, EX 1.6 0.016 0.059
GE, MET, EX 1.5 0.042 0.084
MET, RPPA, EX 1.8 0.011 0.075
lenge, that is, the weighted averaged probabilistic concordance in-
dex. We achieved a score of 0.592, which would have been placed
the first in the challenge (winner model reaching 0.583), indicat-
ing excellent prediction performance of GFA on this data, possibly
stemming from the biclustering nature of the model. Furthermore,
we ran GFA utilizing data sources paired in two modes in a similar
way with additional functional connectivity fingerprints describing
the drugs (FCFP; calculated with PaDEL-Descriptor, Yap (2011)),
allowing joint modelling of biological and chemical effects in the
measured data. The additional chemical view resulted in a slight in-
crease in the target score, to 0.599.The structure of the latter model
is interpreted in the following sections, motivated by the excellent
predictive performance.
4.1 Robust components
For interpretation purposes we next sought representative point so-
lutions to describe the posterior distributions. Due to the extremely
challenging nature of the problem the total variance explained by
individual components is small. To minimize the risk of analysing
patterns occurred by chance, we searched for components that oc-
cur consistently across the different sampling chains, making the
assumption (which was checked manually) that component indices
are reasonably stable within a chain, but can naturally be arbitrar-
ily permuted between chains. To find the matches between chains
we averaged the components over the posterior samples within their
chain, and compared using cosine similarity. If the similarity of the
best match exceeded the threshold 0.80, we considered the com-
ponents to be the same. Furthermore, we chose to further study
components found in at least half of all chains, deemed robust in
this procedure. Out of the average 52.6 components inferred by the
sampling chains, 25 were on average chosen to the set of robust
components. Ideally we would infer the model parameters with a
single well-mixing sampling chain, but as the posterior is multi-
modal (and we do not want to constrain it artificially) the inference
problem is extremely challenging, and we resort to the described
computational simplification.
We observed that some of the components are very sparse, only
containing one or two cell lines and hence most probably explaining
outliers in the data. Therefore, we will focus the interpretations on
the more dense biclusters only; 3 out of the total 27 biclusters found
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predicted 1.26%, 0.06% and 0.11% of the total variance in the test
data (2.89%, 0.3% and 0.98% in the set of active drugs). There
was 1 additional bicluster shared with the drug descriptors, but it
had no significant effect to the test data. With the drug sensitivity
prediction of these four components only, we received a target score
of 0.591.
4.2 Interpretations of the biclusters
For interpretation purposes, we collected the descriptions of the
drugs and cell lines used in the challenge (Costello et al., 2014).
Some groups of drugs can be identified, which we will abbrevi-
ate as: autophagy (au), cell cycle (cc), metabolism (me), regulation
(re) and signalling growth (gr) drugs, as well as nuclear factor (nf),
protease (pr) and receptor tyrosine kinase (rtk) inhibitors. Further-
more, most of the cell lines represent a subtype of cancer which can
be categorized as basal or luminal.
The bicluster structure of the activity patterns for the first compo-
nent in the drug sensitivity (DS) view, consisting of measurements
of sensitivity of cell lines to drugs, is depicted in Fig. 3a. Com-
ponent one distinguishes basal and luminal cell types, without that
information being used in the training. The response for all 5 cell
cycle and all 4 metabolism drugs is positive or above average for
most of the basal cell lines, whereas luminal cells show negative ac-
tivation. Luminal cells respond strongly to regulation drugs, where
the response of basal cells is negative. Component 2 shows high
activity patterns for proteasome and cell cycle drugs as depicted in
Fig. 3b. The other components have relatively small biclusters with
only a few active cells and drugs. Component 3, for example, shows
cells that are (un)responsive to rtk inhibitors and otherwise mixed
groups of cells and drugs (see Fig. 3c). The remaining robust com-
ponent, in the second mode, was associated with most of the drugs
and drug descriptors, and weakly with approximately half of the
cell lines (strongly with T47DKBLUC).
Due to the large number of genes in the other views, we show
summaries of enrichment of known cancer genes in the compo-
nents. We performed hypergeometric tests comparing a varying
number of the most active genes (i.e. genes with the highest mean
absolute values in W corresponding to RPPA and GE views) and
random sets of equal size, for the occurrence of known cancer genes
(extracted from Stephens et al. (2012)) in the most predictive com-
ponents and all views. Low p-values indicate that the approach is
able to detect a significant amount of known (breast) cancer genes
in the top active genes of the components when compared to ran-
dom subsets of genes in the views. Fig. 4 shows the results of the
hypergeometric test for two robust components. For component 1
(Fig. 4a) we observe highly significant cancer activity already in
the 10 most active genes in every view, except in the RPPA data. In
the Exome sequence data we observe significant cancer gene activ-
ity independently of the size of the subset. For component 2 (Fig.
4b) we observe less significant activity of cancer genes in the gene
expression and exome data than in component 1. However, we find
high cancer gene activity in the methylation view and very high ac-
tivity of breast cancer genes in exome sequencing data.
Besides the statistical tests we report the results on the level of
individual genes. We condensed the analysis showing the 50 most
active genes (in terms of their absolute values) in component 1 in
the gene expression (Fig. 3d) and the RPPA view in Fig. 3e. Com-
ponent 1 contains proportional and anti-proportional co-regulated
genes as indicated by the intensity of the biclusters depicted. The
genes which are known as cancer or breast cancer genes are marked
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(b) Cancer gene activity in component 2
Fig. 4: Hypergeometric test of the activity of known breast cancer (BC) and
all cancer (C) genes in the two most predictive components and all views.
Low P-values indicate a high number of cancer genes in the top n active
genes in comparison with randomly picked sets. See the text for details.
by a black and gray squares, respectively. Fig. 3f summarizes
the mean participation in biclusters of the cells in seven different
components on the top 10 active genes in each of the views. The
left side contains the list of all cells sorted by their mean absolute
values in the seven most active components, which are depicted
in the middle row. The right side contains the list of top genes
clustered by their mean activity in these components, accompanied
by a shortcut for the view they were taken from and [C] in case
they are known as cancer gene in the literature. Component one
(coloured red) contains the biggest biclusters with comparably high
mean absolute values depicted by thicker connecting lines in lots
of cells and genes throughout the different views except the exome
sequence data. Even only selecting 10 most active genes from each
view delivers at least one known cancer gene. Although compo-
nents overlap they also depict relationships of different cells in dif-
ferent views.
Furthermore, we performed a Gene Ontology (GO) enrichment
analysis on the most active gene sets in the components and gene
related views. In GO the genes or gene products are hierarchically
classified and grouped into three categories: molecular function
(mf) describing the molecular activity of a gene, biological process
(bp) denoting the larger cellular role and cellular component (cc)
depicting where the function is executed in the cell. The enrich-
ment analysis was performed directly in the GO website (http:
//geneontology.org/), which connects the PANTHER (Mi
et al., 2013) classification system with GO annotations. From each
of the gene-related views GE, MET, RPPA and EX we selected a
list of the 50 most active genes from the dense robust components.
For each of such gene sets we calculated the enrichment for all cat-
egories. The result table contains a list of shared GO terms for
each gene set together with information about the background and
sample frequency, fold enrichment and the p-value determined by a
binomial statistic. A p-value close to zero indicates the significance
of the GO term associated with the provided group of genes.
More than one thousand shared GO terms are returned for the
most active gene sets. We condensed the results showing only the
most repeating and most significant ones by using a threshold for
the p-value and showing only GO terms below 10−6, which appear
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(b) DS: Robust Component 2
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(c) DS: Robust Component 5
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(d) Top 50 Genes in GE view
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(e) Top 50 Genes in RPPA view
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(f) Summary 7 robust components: Cell lines and top 10 genes in all views
Fig. 3: Bicluster activity patterns of robust components. (a)-(c) show the intensity values of cells (in rows) and drugs (in columns) in the drug sensitivity
(DS) view of 3 different components. Component one mainly distinguishes basal and luminal cell lines, while (d) and (e) show the corresponding
bicluster activity pattern of the 50 genes with highest mean absolute values in the RPPA and GE views, marking known (breast) cancer genes by a (gray)
black square. (f) shows bicluster participation of all cells (left) in 7 selected robust components (middle) with respect to their mean absolute intensity
values (represented in the thickness of the lines) for the top 10 genes in each of the views (GE, MET, RPPA and EX). Known cancer genes are marked
by [C].
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Fig. 5: Enrichment of the most significant GO terms, which occur more
than 3 times in all the gene related views and the three dense robust com-
ponents.
throughout the views and components more than 3 times. Fig. 5
shows the reduced list of significant GO terms with fold enrichment
value bigger than 3. This value indicates the magnitude of fold en-
richment for the observed set of genes over the expected, thus with
values bigger than one the category implying over-representation.
For biological process we found most of the repeating significant
GO terms in all of the views in nearly all cases. These GO terms
are related to cell motility and its regulations.
5 Discussion
We presented sparse group factor analysis as a way of inferring bi-
clusters from heterogeneous multi-source data. The method is able
to detect predictive and interpretable structure present in any subset
of the data sources, and sparse within the sources. It proved to be
robust in this task, as witnessed by the simulation studies and the
outstanding performance in the NCI-DREAM drug sensitivity pre-
diction challenge. The biclusters of the joint data identified cancer
cell subtypes, grouped drugs by their functional mechanisms, and
associated known cancer genes with the drug sensitivity data, all
in a data-driven fashion. The shown approach is suitable for ex-
ploratory analysis of multiple data sources, giving condensed and
interpretable information with respect to the data collection.
In this paper we focused on formulating a model that implements
the novel multi-data-source biclustering, and on evaluating the ac-
curacy of the results. Two important questions we did not yet
fully address are: (i) Could some of the alternative ways of im-
plementing sparsity, substituting the spike-and-slabs of this paper,
result in computationally more efficient and still as accurate so-
lutions. (ii) Computational speed. The EM point estimates the
single-data-source FABIA algorithm uses would naturally be faster
for multiple data sources as well, but the ability to handle uncer-
tainty due to highly noisy and high-dimensional small sample-size
data would suffer. Variational approximations would be attractive
as they would also help avoid the matchings between the differ-
ent sampling chains, but deriving variants of the algorithm would
be more difficult and variational approximations are known to pro-
duce a biased estimate of the uncertainty of the solutions. For large
data parallelised sampling solutions would be particularly attractive
ways of speeding up computation.
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